Lexicon Pharmaceuticals (LXRX) Net Cash Flow (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Net Cash Flow of $3.8 million for Q1 2026, up 199.87% year-over-year from $1.3 million in Q1 2025, and up 124.55% quarter-over-quarter from -$15.3 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Net Cash Flow (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Net Cash Flow for 17 consecutive years, with $3.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 199.87% year-over-year to $3.8 million; the TTM figure through Mar 2026 stood at $4.2 million (up 112.5% YoY), while the FY2025 annual figure was -$3.3 million, down 107.54% from the prior year.
- Net Cash Flow advanced to $3.8 million in Q1 2026 per LXRX's latest filing, from -$15.3 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $76.3 million in Q2 2023 and bottomed at -$81.2 million in Q3 2023.
- Historically, Net Cash Flow has averaged $177882.4 across 5 years, with a median of -$2.6 million in 2022.
- Annual changes were most pronounced in 2023 — Net Cash Flow sank 3002.26% — and 2025, when it surged 2754.03%.
- Lexicon Pharmaceuticals' Net Cash Flow stood at $27.5 million in 2022, then slumped by 95.1% to $1.3 million in 2023, then jumped by 2279.91% to $32.1 million in 2024, then slumped by 147.75% to -$15.3 million in 2025, then soared by 124.55% to $3.8 million in 2026.
- Business Quant data shows LXRX's Net Cash Flow at $3.8 million in Q1 2026, -$15.3 million in Q4 2025, and $28.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | -26.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.17 Mn |
| Jun 30, 2026 | -26.17 Mn |
| Mar 31, 2026 | 3.76 Mn |
| Mar 31, 2026 | 3.76 Mn |
| Dec 31, 2025 | -15.33 Mn |
| Dec 31, 2025 | -15.33 Mn |
| Sep 30, 2025 | 28.29 Mn |
| Sep 30, 2025 | 28.29 Mn |
| Jun 30, 2025 | -12.52 Mn |
| Jun 30, 2025 | -12.52 Mn |
| Mar 31, 2025 | -3.77 Mn |
| Mar 31, 2025 | -3.77 Mn |
| Dec 31, 2024 | 32.11 Mn |
| Dec 31, 2024 | 32.11 Mn |
| Sep 30, 2024 | -1.07 Mn |
| Sep 30, 2024 | -1.07 Mn |
| Jun 30, 2024 | -60.88 Mn |
| Jun 30, 2024 | -60.88 Mn |
| Mar 31, 2024 | 74.03 Mn |
| Mar 31, 2024 | 74.03 Mn |